Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello there. Today, we learn the FDA is advancing a trial for gene-edited pig organs in humans, see geographical discrepancies in lung cancer trial data, and more.
The need-to-know this morning
- A positive readout of a Rapport Therapeutics seizure medicine in a mid-stage clinical trial sent company shares soaring, as the biotech announced it would move the experimental drug into Phase 3 trials. Read more from STAT reporter Andrew Joseph.
- Dianthus Therapeutics said its experimental treatment for myasthenia gravis achieved the primary goals of a Phase 2 study.
- Pfizer and BioNTech reported top-line Phase 3 study results showing their Covid-19 vaccine Comirnaty elicited an immune response against the most prevalent circulating strain of the SARS-Cov-2 virus.
Arena BioWorks refocuses with a new CEO
Arena BioWorks, the $500 million research institute launched last year by billionaire backers, has tapped ARIAD Pharmaceuticals co-founder Harvey Berger as CEO, reuniting him with longtime collaborator Stuart Schreiber, who shifts to chief scientific officer. The move follows a 30% staff cut that largely eliminated the company’s gene and cell therapy group, STAT’s Allison DeAngelis writes, with Berger arguing the institute had been overextended.
Continue to STAT+ to read the full story…
